Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)








Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Pneumococcal Vaccines for Adults aged ≥65 years						Print
																Related Pages
										On This Page
			MethodsTablesReferences
		
Printer friendly version of this page [9 pages]
Methods
GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) for routine use among adults aged ≥65 years.  Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods.[1] The primary policy question was “Should PCV13 be administered routinely to all adults aged ≥65 years?” The intervention evaluated was a single dose of PCV13 compared to a dose of 23-valent polysaccharide vaccine (PPSV23).
The benefits considered critical outcomes in GRADE included prevention of invasive pneumococcal disease (IPD), pneumococcal community-acquired pneumonia, and hospitalizations due to pneumococcal disease. Evidence used to evaluate efficacy of PCV13 against IPD and pneumococcal pneumonia was from the randomized placebo-controlled trial (RCT) conducted among approximately 85,000 adults aged ≥65 years in Netherlands (CAPiTA).[2]  Evidence was not available for the critical outcome of hospitalizations due to pneumococcal disease. In addition, vaccine-induced immunogenicity was considered as an important outcome; immunogenicity evidence was assessed using two phase III RCTs of PCV13 compared to PPSV23, which measured antibody responses by opsonophagocytic assay (OPA) and four RCTs of PCV7 compared to PPSV23, which measured antibody responses by enzyme-linked immunosorbent assay (ELISA).[3-8]
The harms considered were overall serious adverse events (SAE), deaths and systemic adverse events including fatigue, rash, new generalized muscle pain, and use of medications to treat fever.  Safety of PCV13 was evaluated based on 6 RCTs in immunocompetent adults, compared to PPSV23.[9]
Evidence type for each critical outcome was derived through a review of study design, risk of bias, inconsistency, indirectness, and imprecision.
**Top of Page
Tables
Table 1a Benefits of 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥65 years:
Invasive Pneumococcal Disease and Community-Acquired Pneumonia
Benefits of 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥65 years
Outcome
No. of subjects (# studies)
Incidence in unvaccinated (cases/100,000)
Vaccine efficacy (95% CI)
Number Needed to Vaccinate aPCV13-serotype Invasive Pneumococcal Disease
Approximately 85,000 adults
(1 RCT)[2]
6.5[10]
74% (30-90%) b
20,400 (16,950 – 37,000)Inpatient community-acquired pneumonia
Approximately 85,000 adults
(1 RCT)[2]
137.5[11] c
45% (14-65%)
1,620 (1,110 – 5,130)Outpatient community-acquired pneumonia
Approximately 85,000 adults
(1 RCT)[12]
201[9] c
45% (14-65%)
1,110 (760-3,500)Total community-acquired pneumonia
Approximately 85,000 adults
(1 RCT)[2]
—
—
656 (454-2,110)Table 1a Footnotes
a Number needed to vaccinate or NNV=1 / (baseline rate — vaccinated rate) b Vaccine Efficacy versus placebo c Baseline estimates assume 10% of all CAP due to PCV13 types
**Top of Page
Table 1b Benefits of 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥65 years:
Immunogenicity a
Benefits of 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥65 years
Study
No. of subjects
Population
Immunogenicity ResultsJackson et al 2013[3]
818
60 to 64 years
PPSV23 Naïve
PCV13 > PPSV23 for 9/13 types (OPA)
PCV13=PPSV23 for 4/13 types (OPA)Jackson et al 2013[4]
879
≥70 years
PPSV23 >5 years previously
PCV13>PPSV23 for 11/13 types (OPA)
PCV13=PPSV23 for 2/13 types (OPA)Goldblatt et al 2009[5]
599
50 to 80 years
No PPSV23 *within the past* 5 years
PCV7 = PPSV23 for 3/7 types (ELISA)
PCV7 > PPSV23 for 3/7 types (ELISA)
PCV7<PPSV23 for 1/7 types (ELISA)De Roux et al 2008[6]
217
>70 years
PPSV Naïve
PCV7 = PPSV23 for 1 type  (ELISA)
PCV7>PPSV23 for 6/7 types (ELISA)Ridda et al 2009[7]
241
>60 years, frail
PPSV Naïve
PCV7 = PPSV23 for 4/4 types tested   (ELISA)
Comparisons of other 3 types not doneMiernyk et al 2009[8]
203
55 to 70 years, Alaska Native
PPSV Naïve
PCV7 = PPSV23 for 4/4 types tested (ELISA)
Comparisons of other 3 types not doneTable 1b Footnotes
a Immunogenicity: Antibody response to vaccine serotypes, compared to PPSV23
**Top of Page
Table 2. Harms of 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥65 years
Harms of 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥65 years
Outcome
No. of subjects
Incidence in controls
Incidence in vaccinated
Risk Difference per 1000 (95% CI)Serious adverse events (SAE)Overall serious adverse events
6,000
(6 RCTs)[9]
—
0.2-1.1%
No difference aDeaths
6,000
(6 RCTs)[9]
—
16/6000 (0.3%) b
No difference aSystemic Adverse EventsFatigue
3 RCTs &
PCV13 phase III[9] c
43.3% d
34.0%
-9.3
(-16.4, -2.2)Rash
3 RCTs &
PCV13 phase III[9] c
16.4% d
7.3%
-9.1
(-14.3, -4.0)New generalized muscle pain
3 RCTs &
PCV13 phase III[9] c
44.7% d
36.8%
-7.9
(-15.2,-0.6)Medications to treat fever
3 RCTs &
PCV13 phase III[9] c
17.5% d
8.6%
-8.9
(-16.6,-1.9)Table 2 Footnotes
a No difference between the treatment groups b No deaths were considered vaccine related c Significant differences reported for 2 out of 3 RCTs (4 out of 13 outcomes); only significant findings presented in the table d Controls received PPSV23
**Top of Page
Table 3. Evidence Type for Benefits and Harms: 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥65 years
Evidence Type for Benefits and Harms: 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥65 years
Outcome
Study design
Risk of Bias
Inconsistency
Indirectness
Imprecision
Evidence Type aBenefits bInvasive Pneumococcal Disease
1 RCT
No serious
Not applicable
Serious
No serious
2Community-acquired pneumonia
1 RCT
No serious
Not applicable
No serious
No serious
1Immunogenicity
6 RCT
No serious
No serious
Serious
No serious
2HarmsSystemic adverse events
3 RCTs
No serious
No serious
No serious
No serious
1Table 3 Footnotes
a Evidence type:
Randomized controlled trials (RCTs), or overwhelming evidence from observational studies.
RCTs with important limitations, or exceptionally strong evidence from observational studies.
Observational studies, or RCTs with notable limitations.
Clinical experience and observations, observational studies with important limitations, or RCTs with several major limitations.b Immunogenicity data which was considered an important outcome did not contribute to overall evidence type. c Indirectness due to different comparison group: 1) Placebo instead of PPSV and 2) PPSV efficacy against IPD among older adults = 50-80% d Indirectness due to different outcome (antibody response without correlates of protection)
**Top of Page
Table 4. Summary of Evidence for 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥65 years
Summary of Evidence for 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥65 years
Comparison
Outcome
Study design
Findings
**Evidence type**
**Overall evidence type** aPCV13 vs. no vaccination
IPD
1 RCT
Decreased risk among vaccinated
2
2PCV13 vs.
no vaccination
Pneumonia
1 RCT
Decreased risk among vaccinated
1
2PCV7 or PCV13 vs.
PPSV23
Immunogenicity
6 RCTs
Response better for PCV than PPSV23 or no difference
2
2PCV13 vs.
PPSV23
Serious and systemic adverse events
3 RCTs
No difference or decreased risk with PCV13
1
2Table 4 Footnotes
a Overall evidence type is based on the weakest evidence type among the critical outcomes.  This did not include immunogenicity data which was considered an important outcome.
**Top of Page
Table 5. Considerations for Formulating Recommendations for 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥ 65 years
Considerations for Formulating Recommendations for 13-valent Pneumococcal Conjugate Vaccine in Adults aged ≥ 65 years
Key factors
CommentsEvidence type/quality for benefits and harms
Data on efficacy against most critical outcomes availableBalance of benefits versus harms
Benefits outweigh harms
Short-term: No uncertainty about the balance
Long-term:  Indirect (herd) effects of infant vaccination expected to further reduce burden of pneumococcal disease in adultsValues
General consensus reached on which outcomes are critical to preventCost-effectiveness
Short-term: The net benefits are worth the costs
Long-term: Uncertainty about whether the net benefits are worth the costs due to continued indirect effectsSummary
The evidence supporting PCV13 vaccination of adults was determined to be type 2 (moderate level of evidence).
The recommendation was designated as Category A.
The ACIP Pneumococcal Work Group concluded that broader serotype protection can be achieved through use of both PCV13 and PPSV23 among adults >65 years of age; 20-25% of IPD among adults in this age group is caused by PCV13 serotypes, and an additional 38.5% by serotypes in PPSV23 not included in PCV13.[10]  Conversely, PCV13 use among older adults will protect against inpatient community-acquired pneumonia.[2]  Evidence from immunogenicity studies demonstrate that antibody response is non-inferior or superior when PCV is given before PPSV23 compared to PPSV23 administration before PCV.[3-8]  Although the optimal interval for PCV13 followed by PPSV23 has not been directly studied, studies evaluating the immune response following a sequence of PCV7 or PCV13 followed by PPSV23 with intervals of 2, 6, 12 months, or 3-4 years demonstrated that following the PPSV23 dose, antibody levels were higher than the pre-PCV baseline, and a non-inferior response was observed when compared with post-PCV antibody levels.[5],[8],[13],[14] For adults previously immunized with PPSV23, waiting at least 1 year after PPSV23 before giving a dose of PCV13 may provide a better immune response according to expert opinion.
**Top of Page
References
Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). *Vaccine.* 2011;29(49):9171-9176.
Bonten M, Bolkenbaas M, Huigts S, et al. Community Acquired Pneumonia Immunization Trial in Adults (CAPITA) Abstract # 0541 [3.91 MB, 289 pages]. *International Symposium on Pneumococci and Pneumococcal Diseases* 2014.
Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. *Vaccine.* 8/2/ 2013;31(35):3577-3584.
Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Vaccine.* 8/2/ 2013;31(35):3585-3593.
Goldblatt D, Southern J, Andrews N, et al. The Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine in Adults Aged 50–80 Years. *Clinical Infectious Diseases.* November 15, 2009 2009;49(9):1318-1325.
de Roux A, Schmidt N, Rose M, Zielen S, Pletz M, Lode H. Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. *Respir Med.* Dec 2004;98(12):1187-1194.
Ridda I, MacIntyre CR, Lindley R, et al. Immunological responses to pneumococcal vaccine in frail older people. *Vaccine.* 2009;27(10):1628-1636.
Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55-70 Years of Age. *Clinical Infectious Diseases.* July 15, 2009 2009;49(2):241-248.
US Food and Drug Administration. *Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13.* Silver Spring, MD2011.
Active Bacterial Core Surveillance (ABCs): Emerging Infections Program Network. Unpublished 2013 ABCs Data on *Streptococcus Pneumoniae*. Vol 2014: CDC; 2013.
Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. *The Lancet Respiratory Medicine.* 2014;2(5):387-394.
Nelson JC, Jackson M, Yu O, et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. *Vaccine.* Sep 8 2008;26(38):4947-4954.
Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age. *Vaccine.* 4/25/ 2014;32(20):2364-2374.
Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. *Vaccine.* 8/2/ 2013;31(35):3594-3602.**Top of Page
					View Page In:PDF [796K]		
					
							Last Reviewed:  April 15, 2016						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue